SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Radiation Oncology Consultation — Nelson Mandela

PatientNelson Mandela
Date of birth1943-07-18
IdentifiersMRN HR-ML021-SYN; SSN (made up) 000-21-6718
Document date2026-04-14
AuthorPieter van Zyl, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Man of 82 with newly diagnosed prostate adenocarcinoma, Grade Group 3, PSA 6.4 ng/mL, cT1c, NCCN unfavorable intermediate risk, found after a rising PSA on monitoring. Please advise on curative treatment, including radiotherapy with short-term androgen deprivation, and whether observation is reasonable at his age. [S]

Urgency: Routine, within four to six weeks. [S]

Questions for the consultant:

History of Present Illness

Mr. Mandela is seen at the request of Dr. Mokoena for newly diagnosed prostate cancer. A rise in PSA on routine monitoring led to an MRI and a targeted biopsy, which showed Grade Group 3 adenocarcinoma in 3 of 14 cores. He has mild urinary frequency, with an IPSS of 7, and no bone pain, weight loss, or blood in the urine. Decades ago part of his prostate was removed for benign enlargement. He had tuberculosis in the past, treated, with no symptoms since. He is independent, walks every morning, and keeps a full schedule of work and travel. He wants to understand all the options before deciding. [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolideOne tablet once daily for four weeksOral route2026-04-14 to 2026-05-12completedS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-04-14activeS

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate canceractiveconfirmed C61S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D).
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognitionactiveconfirmed Z79.899S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
History of pulmonary tuberculosis, treated, with no symptoms sinceresolvedconfirmed Z86.11S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic.

Physical Exam

Vital signs recorded on 2026-04-14; see the referring visit's Vital Signs section. [S]

SystemFinding
GeneralWell
AbdomenSoft; bladder not palpable
MusculoskeletalNo spinal tenderness
Lymph nodesNo inguinal or supraclavicular nodes

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-14DXA Femur [T-score] Bone density-1.4{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisLowS
2026-04-14DXA Lumbar spine [T-score] Bone density-0.6{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisNormalS
2026-04-14Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Assessment

Data reviewed: MRI prostate report and images, biopsy pathology, the first-visit PSA, testosterone, blood count, chemistry, A1c, lipids, and 25-hydroxyvitamin D, the PSMA PET/CT from two weeks ago (uptake confined to the left peripheral zone; no nodal, bone, or visceral disease), and the DXA scan from this morning (femoral neck T-score -1.4, lumbar spine -0.6). [S]

Plan of Treatment